行情

SYN

SYN

SYNTHETIC
AMEX

实时行情|Nasdaq Last Sale

0.4625
+0.0142
+3.17%
交易中 14:36 09/21 EDT
开盘
0.4600
昨收
0.4483
最高
0.4700
最低
0.4550
成交量
71.87万
成交额
--
52周最高
1.700
52周最低
0.2610
市值
6,106.97万
市盈率(TTM)
-1.0598
分时
5日
1月
3月
1年
5年
肠易激综合征药物市场：预计复合年增长率、该地区和全球的顶级制造商和消费者分析、到 2029 年的机会和增长
Research Nester published a report titled which delivers detailed overview of the irritable bowel drugs market in terms of market segmentation by type, by product, by end user and by region.
AmericaNewsHour · 09/08 06:26
肠易激综合征药物市场 - 2029 年全球最新统计数据、发展领域和新兴机会
Research Nester published a report titled which delivers detailed overview of the irritable bowel drugs market in terms of market segmentation by type, by product, by end user and by region.
AmericaNewsHour · 09/03 13:51
合成生物制剂 EPS 在线
Synthetic Biologics (NYSE:SYN): Q2 GAAP EPS of -$0.02 in-line. Current cash position of approximately $74.3M. "During the second quarter, we remained focused on the advancement of our portfolio of gastrointestinal
Seekingalpha · 08/05 20:39
BRIEF-Synthetic Biologics Posts Q2 Loss Per Share $0.02
reuters.com · 08/05 20:18
Synthetic Biologics 报告 2021 年第二季度运营亮点和财务业绩；电话会议将于今天美国东部时间下午 4:30 举行
/PRNewswire/ -- (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of high unmet need, today provided a clinical programs upda...
PR Newswire - PRF · 08/05 20:10
每日生物技术脉搏：默克报告了积极的 Keytruda 读数，尽管第二季度节拍，Moderna 下滑，拜耳以高达 $2B 的价格购买 Vividion，GlycoMimetics 获得新的首席执行官
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)
Benzinga · 08/05 12:04
Brief-Synthetic Biologics 扩大了与马萨诸塞州综合医院的独家许可协议的选择权
reuters.com · 08/03 11:40
Synthetic Biologics 报告扩大与马萨诸塞州综合医院独家许可交易的选择权
Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of
Benzinga · 08/03 11:22
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解SYN最新的财务预测，通过SYN每股收益，每股净资产，每股现金流等数据分析SYNTHETIC近期的经营情况，然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测SYN价格均价为1.875，最高价位2.500，最低价为1.250。
EPS
机构持股
总机构数: 29
机构持股: 174.67万
持股比例: 1.32%
总股本: 1.32亿
类型机构数股数
增持
3
25.34万
建仓
2
9.81万
减持
6
4.74万
平仓
5
52.36万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.37%
制药与医学研究
+0.74%
高管信息
Non-Executive Chairman/Independent Director
Jeffrey Kraws
Chief Executive Officer/Chief Financial Officer/Director
Steven Shallcross
Independent Director
John Monahan
Independent Director
Jeffrey Wolf
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
SYN 简况
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics designed to treat gastrointestinal (GI) diseases. The Company's lead product candidates in Phase III development are SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and Phase II SYN-010 which reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company also develops SYN-020, an early-stage oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.

微牛提供Synthetic Biologics Inc(AMEX-SYN)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的SYN股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易SYN股票基本功能。